Oncternal Therapeutics (NASDAQ:ONCT – Free Report) had its target price cut by HC Wainwright from $19.00 to $18.00 in a research note issued to investors on Monday morning, Benzinga reports. They currently have a buy rating on the stock.
Separately, StockNews.com assumed coverage on Oncternal Therapeutics in a research note on Wednesday, August 7th. They issued a hold rating for the company.
Read Our Latest Stock Report on Oncternal Therapeutics
Oncternal Therapeutics Trading Down 6.2 %
Oncternal Therapeutics (NASDAQ:ONCT – Get Free Report) last released its quarterly earnings data on Thursday, August 8th. The company reported ($2.89) earnings per share (EPS) for the quarter, beating the consensus estimate of ($3.03) by $0.14. Oncternal Therapeutics had a negative return on equity of 107.67% and a negative net margin of 3,160.73%. The company had revenue of $0.80 million during the quarter, compared to the consensus estimate of $0.24 million. During the same quarter in the prior year, the firm posted ($3.00) earnings per share. On average, sell-side analysts predict that Oncternal Therapeutics will post -11.63 earnings per share for the current year.
Institutional Trading of Oncternal Therapeutics
An institutional investor recently bought a new position in Oncternal Therapeutics stock. Quantum Private Wealth LLC purchased a new position in shares of Oncternal Therapeutics, Inc. (NASDAQ:ONCT – Free Report) during the first quarter, according to its most recent 13F filing with the SEC. The institutional investor purchased 27,806 shares of the company’s stock, valued at approximately $250,000. Quantum Private Wealth LLC owned approximately 0.94% of Oncternal Therapeutics as of its most recent filing with the SEC. Institutional investors and hedge funds own 16.05% of the company’s stock.
Oncternal Therapeutics Company Profile
Oncternal Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the development of oncology therapies for cancers with critical unmet medical needs. The company's clinical pipeline includes zilovertamab, a humanized monoclonal antibody that binds to receptor-tyrosine kinase-like Orphan Receptor 1 (ROR1); and ONCT-216, a small molecule inhibiting the biological activity of ETS-family transcription factor oncoproteins, which is in Phase 1/2 clinical trial.
Read More
- Five stocks we like better than Oncternal Therapeutics
- Dividend King Proctor & Gamble Is A Buy On Post-Earnings Weakness
- Michael Burry’s Alibaba Bet and the Broader Market Implications
- What is a buyback in stocks? A comprehensive guide for investors
- Jeff Brown’s Exegesis AI Stock Picks
- Should You Add These Warren Buffett Stocks to Your Portfolio?
- Warren Buffett’s Bet: Why Berkshire Hathaway Bought Ulta Stock
Receive News & Ratings for Oncternal Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Oncternal Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.